Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Intramedullary

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Intramedullary. Displaying page 1 of 1.
    EudraCT Number: 2016-003213-98 Sponsor Protocol Number: LFCN_1-1_20160802 Start Date*: 2016-10-14
    Sponsor Name:Dep. Anaesthesia and Intensive Care, Aarhus University Hospital
    Full Title: The lateral femoral cutaneous nerve – description of the sensory territory and a novel ultrasound guided nerve block technique
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10036236 Postoperative pain relief LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008392-34 Sponsor Protocol Number: 20062017 Start Date*: 2009-08-27
    Sponsor Name:Amgen Inc
    Full Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Study of AMG 785 in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture Status Post Definitive Fracture Fixation...
    Medical condition: Acceleration of fracture healing
    Disease: Version SOC Term Classification Code Term Level
    13.1 10022117 - Injury, poisoning and procedural complications 10043827 Tibia fracture PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) DK (Completed) GB (Completed) DE (Completed) FR (Completed) GR (Completed) IT (Completed) BG (Completed) HU (Completed) LT (Completed) EE (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2015-002383-16 Sponsor Protocol Number: CME-LEM4 Start Date*: 2016-01-19
    Sponsor Name:Fundación Investigación Biomédica Hospital Universitario Puerta de Hierro
    Full Title: Evaluate the efficacy of the cell therapy with NC1 medication in patients with post-traumatic syringomyelia
    Medical condition: Traumatic spinal cord injury, chronically established, associated with syringomyelia and neurological deficit considered irreversible.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-004045-16 Sponsor Protocol Number: ET18-272 Start Date*: 2019-03-14
    Sponsor Name:Centre Léon Bérard
    Full Title: REGOSTA – A randomized, placebo-controlled, double-blinded, multicentre study evaluating the efficacy and safety of regorafenib as maintenance therapy after first-line treatment in patients with bo...
    Medical condition: Patients with bone sarcomas other than Ewing sarcoma or chondrosarcoma or chordoma, who have no residual disease after neoadjuvant chemotherapy, surgery and/or adjuvant chemotherapy.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002629-31 Sponsor Protocol Number: ET19-144 Start Date*: 2021-01-07
    Sponsor Name:Centre Léon Bérard
    Full Title: REGOMAIN – A randomized, placebo-controlled, double-blinded, multicentre, comparative phase II study of the efficacy of regorafenib as maintenance treatment in patients with high grade bone sarcoma...
    Medical condition: Patients with high grade bone sarcomas (HGBS) at diagnosis or first relapse and without complete remission after standard treatment
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001831-23 Sponsor Protocol Number: 3100N7-210 WW Start Date*: 2007-01-23
    Sponsor Name:Wyeth Pharmaceuticals Inc.
    Full Title: A Phase 2/3, Multicenter, Double-Blind, Randomized, Controlled Study of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP 2)/Calcium Phosphate Matrix (CPM) in Closed Diaphyseal Tibial Fractures
    Medical condition: Closed diaphyseal tibial fracture
    Disease: Version SOC Term Classification Code Term Level
    8.1 10043827 Tibia fracture LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SE (Completed) DE (Prematurely Ended) FI (Completed) GB (Completed) LV (Completed) SI (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-006060-89 Sponsor Protocol Number: NMSG29/21 Start Date*: 2021-03-26
    Sponsor Name:Odense University Hospital
    Full Title: Selinexor with alternating bortezomib or lenalidomide plus dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients (SABLe): An Investigator Sponsored Trial
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-015939-33 Sponsor Protocol Number: 20080394 Start Date*: 2010-03-23
    Sponsor Name:Amgen Inc
    Full Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy, Safety, and Tolerability of AMG 785 in Adults with Fresh Unilateral Intertrochanteric Fracture of the P...
    Medical condition: Acceleration of fracture healing
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) SE (Completed) PL (Completed) DK (Completed) NL (Completed) LV (Completed) GR (Completed) IT (Completed) HU (Completed) BE (Completed) FI (Completed) LT (Completed) EE (Completed) BG (Completed) SI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 23:19:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA